Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wick, W.
Right arrow Articles by Weller, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wick, W.
Right arrow Articles by Weller, M.
Related Collections
Right arrow All Clinical trials
Right arrow All Oncology
Right arrow Primary brain tumor
Right arrow Chemotherapy-tumor
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2004;62:2113-2115
© 2004 American Academy of Neurology
Brief Communications

One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma

W. Wick, MD, J. P. Steinbach, MD, W. M. Küker, MD, J. Dichgans, MD, M. Bamberg, MD and M. Weller, MD

From the Department of General Neurology, Hertie Institute for Clinical Brain Research (W. Wick, J.P. Steinbach, J. Dichgans, and M. Weller), and Departments of Neuroradiology (W.M. Küker) and Radiation Oncology (M. Bamberg), University of Tübingen Medical School, Germany.

Address correspondence and reprint requests to Dr. Wolfgang Wick, Department of General Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany; e-mail: wolfgang.wick{at}uni-tuebingen.de

Twenty-one patients with recurrent or progressive glioblastoma were enrolled in a prospective phase II trial to determine the safety and efficacy of a 1-week on/1-week off regimen of temozolomide administered at 150 mg/m2 on days 1 to 7 and days 15 to 21 of 28-day treatment cycles. Two patients achieved a partial response (10%), and 17 patients (81%) had stable disease. The median progression-free survival was 5 months. The progression-free survival at 6 months was 48%.

Received September 8, 2003. Accepted in final form January 29, 2004.




This article has been cited by other articles:


Home page
 JCOHome page
J. L. Clarke, F. M. Iwamoto, J. Sul, K. Panageas, A. B. Lassman, L. M. DeAngelis, A. Hormigo, C. P. Nolan, I. Gavrilovic, S. Karimi, et al.
Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
J. Clin. Oncol., August 10, 2009; 27(23): 3861 - 3867.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncologyHome page
W. Wick, M. Platten, and M. Weller
New (alternative) temozolomide regimens for the treatment of glioma
Neuro Oncology, February 1, 2009; 11(1): 69 - 79.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L.-K. Bracht, P. Wen, J. A. Meyerhardt, M. H. Kulke, J. L. Hornick, M. Redston, D. C. LaFrankie, P. M. Black, S. Kesari, A. Norden, et al.
DNA Repair Enzyme Expression and Differential Response to Temozolomide in a Patient With Both Glioblastoma and Metastatic Pancreatic Neuroendocrine Tumor
J. Clin. Oncol., October 10, 2008; 26(29): 4843 - 4844.
[Full Text] [PDF]

Home page
 JCOHome page
M. E. Hegi, L. Liu, J. G. Herman, R. Stupp, W. Wick, M. Weller, M. P. Mehta, and M. R. Gilbert
Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
J. Clin. Oncol., September 1, 2008; 26(25): 4189 - 4199.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Beier, S. Rohrl, D. R. Pillai, S. Schwarz, L. A. Kunz-Schughart, P. Leukel, M. Proescholdt, A. Brawanski, U. Bogdahn, A. Trampe-Kieslich, et al.
Temozolomide Preferentially Depletes Cancer Stem Cells in Glioblastoma
Cancer Res., July 15, 2008; 68(14): 5706 - 5715.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncologyHome page
G. Filippini, C. Falcone, A. Boiardi, G. Broggi, M. G. Bruzzone, D. Caldiroli, R. Farina, M. Farinotti, L. Fariselli, G. Finocchiaro, et al.
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma
Neuro Oncology, February 1, 2008; 10(1): 79 - 87.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Nagane, K. Kobayashi, A. Ohnishi, S. Shimizu, and Y. Shiokawa
Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Protein Expression in Patients with Recurrent Glioblastoma Treated with Temozolomide
Jpn. J. Clin. Oncol., December 21, 2007; (2007) hym132v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Wick, J. Felsberg, J. P. Steinbach, U. Herrlinger, M. Platten, B. Blaschke, R. Meyermann, G. Reifenberger, M. Weller, and W. Wick
Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma
J. Clin. Oncol., August 1, 2007; 25(22): 3357 - 3361.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. L. Chinot, M. Barrie, S. Fuentes, N. Eudes, S. Lancelot, P. Metellus, X. Muracciole, D. Braguer, L. Ouafik, P.-M. Martin, et al.
Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide
J. Clin. Oncol., April 20, 2007; 25(12): 1470 - 1475.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. Hau, D. Koch, T. Hundsberger, E. Marg, B. Bauer, R. Rudolph, M. Rauch, A. Brenner, P. Rieckmann, J. Schuth, et al.
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma
Neurology, February 27, 2007; 68(9): 688 - 690.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U. Herrlinger, J. Rieger, D. Koch, S. Loeser, B. Blaschke, R.-D. Kortmann, J. P. Steinbach, T. Hundsberger, W. Wick, R. Meyermann, et al.
Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03
J. Clin. Oncol., September 20, 2006; 24(27): 4412 - 4417.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
E. T. Wong, A. A. Brandes, and A. Tosoni
Is protracted low-dose temozolomide feasible in glioma patients?
Neurology, August 8, 2006; 67(3): 543 - 544.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
I. Y. Eyupoglu, E. Hahnen, C. Trankle, N. E. Savaskan, F. A. Siebzehnrubl, R. Buslei, D. Lemke, W. Wick, R. Fahlbusch, and I. Blumcke
Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275
Mol. Cancer Ther., May 1, 2006; 5(5): 1248 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Tosoni, G. Cavallo, M. Ermani, L. Scopece, E. Franceschi, C. Ghimenton, M. Gardiman, L. Pasetto, V. Blatt, and A. A. Brandes
Is protracted low-dose temozolomide feasible in glioma patients?
Neurology, February 14, 2006; 66(3): 427 - 429.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Oncologist, February 1, 2006; 11(2): 165 - 180.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. Wick and M. Weller
How Lymphotoxic Is Dose-Intensified Temozolomide? The Glioblastoma Experience
J. Clin. Oncol., June 20, 2005; 23(18): 4235 - 4236.
[Full Text] [PDF]

Home page
 NeurologyHome page
E. T. Wong, L. E. Abrey, R. H. Enting, A. Demopoulos, and L. M. DeAngelis
Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide
Neurology, March 8, 2005; 64(5): 934 - 934.
[Full Text] [PDF]